Evidence map›Paper›PMID 42445039›Full record

ArticleACS medicinal chemistry letters2026

Optimization of Pyrazole-Based Activators of Kv3.1.

Paul K Spearing, Vaishali Satpute Janve, Ian M Romaine, Navoda Jayakodiarachchi, Benjamin W Guttentag, Somnath Jana, Kwangho Kim, Jerod S Denton, Craig W Lindsley, Alex G Waterson

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Paul K SpearingWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Vaishali Satpute JanveDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Ian M RomaineVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.
Navoda JayakodiarachchiWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Benjamin W GuttentagVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0009-0003-2325-2796
Somnath JanaWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Kwangho KimWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.
Jerod S DentonDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Craig W LindsleyWarren Center for Neuroscience Drug Discovery, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0003-0168-1445
Alex G WatersonVanderbilt Institute of Chemical Biology, Vanderbilt University, Nashville, Tennessee 37232, United States.ORCID https://orcid.org/0000-0002-0153-5723

Funding

Development of Kv3.1 potentiators for correcting fast-spiking-interneuron hypofunction in schizophrenia and autism spectrum disorderR01MH131721 · NIMH · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Jerod S. Denton · 2023 to 2026
$2.6M
Automated Compound Storage and Retrieval SystemS10OD028715 · OD · VANDERBILT UNIVERSITY · PI BAUER, JOSHUA A. · 2022 to 2022
$741k
NIH HHS S10 OD028715NIMH NIH HHS R01 MH131721
6 · The paper itself

Abstract

Potentiators of the Kv3.1 voltage-gated potassium channel may have utility as therapies for certain CNS disorders. A SAR survey around a previously reported Kv3.1 activator scaffold led to the identification of compounds with superior potency and higher activation levels than reported molecules. We further demonstrated that these compounds show relevant activity in a patch-clamp electrophysiology assay. Together, the defined tractability in the chemotype and the promising biological activity indicate that these compounds may be leads for continued optimization toward therapies for neurological disorders.

Indexed as

CNS drug discoveryion channel researchKv3.1 activationpotassium channel

Identifiers

PMID42445039
PMCPMC13358987

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.